Impacts of low birthweight on kidney development and intergenerational growth of the offspring
Akiyo Sekimoto,
Yoko Takaso,
Haruka Saruyama,
Masataka Ookawa,
Mari Yamamoto,
Takafumi Toyohara,
Daisuke Saigusa,
Tomoko Fukuuchi,
Mayu Otsuka,
Yui Fushiki,
Seiko Yamakoshi,
Kayo Tanaka,
Tomoaki Ikeda,
Tetsuhiro Tanaka,
Nobuyuki Takahashi,
Eikan Mishima,
Emiko Sato
Affiliations
Akiyo Sekimoto
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan; Tohoku Medical and Pharmaceutical University, Sendai, Japan
Yoko Takaso
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan
Haruka Saruyama
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan
Masataka Ookawa
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan
Mari Yamamoto
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan
Takafumi Toyohara
Department of Nephrology, Tohoku University Graduate School of Medicine, Sendai 983-8536, Japan
Daisuke Saigusa
Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, Tokyo 173-8605, Japan
Tomoko Fukuuchi
Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, Tokyo 173-8605, Japan
Mayu Otsuka
Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, Tokyo 173-8605, Japan
Yui Fushiki
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan
Seiko Yamakoshi
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan
Kayo Tanaka
Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
Tomoaki Ikeda
Department of Obstetrics and Gynecology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan
Tetsuhiro Tanaka
Department of Nephrology, Tohoku University Graduate School of Medicine, Sendai 983-8536, Japan
Nobuyuki Takahashi
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan; Department of Nephrology, Tohoku University Graduate School of Medicine, Sendai 983-8536, Japan
Eikan Mishima
Department of Nephrology, Tohoku University Graduate School of Medicine, Sendai 983-8536, Japan; Institute of Metabolism and Cell Death, Helmholtz Zentrum München, 85764 Neuherberg, Germany
Emiko Sato
Division of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 980-8578, Japan; Department of Nephrology, Tohoku University Graduate School of Medicine, Sendai 983-8536, Japan; Corresponding author
Summary: Low birthweight (LBW) increases the risk of adult-onset diseases, including kidney diseases, with intergenerational consequences; however, the underlying mechanisms and effective interventions are unclear. To examine the cross-generational effects of LBW, we established an LBW mouse model through reduced uterine perfusion pressure (RUPP) and investigated the therapeutic potential of tadalafil, a phosphodiesterase 5 inhibitor, on LBW-associated consequences. RUPP-pups (R1) had lower fetal and birth weights, delayed renal development, and fewer glomeruli than Sham-pups. In adulthood, R1 mice exhibited persistently fewer glomeruli and elevated blood pressure, while Tadalafil-R1 mice showed reduced hypertension in both sexes and improved renal pathological changes in males. Additionally, pregnant R1 mice displayed inadequate gestational liver hypertrophy, impaired hepatic purine metabolism, and diminished placental angiogenesis, resulting in fetal growth restriction in the subsequent generation. These findings underscore the lasting impact of LBW on adult health and future generations and suggest tadalafil’s potential to mitigate LBW-associated risks.